HSD17B1-AS1: A Potential Drug Target and Biomarker (G108783654)

Target Name: HSD17B1-AS1

NCBI ID: G108783654

HSD17B1-AS1

Other Name(s): HSD17B1 antisense RNA 1

HSD17B1-AS1: A Potential Drug Target and Biomarker

HSV-1 (Herpes simplex virus 1) is a member of the Herpesviridae family and is responsible for causing painful shingles, chickenpox, and genital herpes. The virus is highly persistent and can reactivate in individuals, leading to the development of neuralgia, which can be a life-threatening complication. HSD17B1-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for Hsv-1.

Synonyms and Structure

HSD17B1-AS1 is a non-coding RNA molecule that contains 21 amino acid residues and has a calculated molecular weight of 18 kDa. The RNA molecule is derived from the HSD17B1 gene, which is located on chromosome 6p21. HSD17B1 is a transmembrane protein that is involved in the development and maintenance of the nervous system. The protein is expressed in a variety of tissues, including brain, skin, and heart, and is involved in the regulation of pain perception and neurotransmitter signaling.

Function and Interaction

HSD17B1-AS1 is involved in the regulation of pain perception and neurotransmitter signaling. The RNA molecule has been shown to play a role in the regulation of pain transmission, with studies suggesting that it may be involved in the modulation of pain sensitivity. HSD17B1-AS1 has also been shown to play a role in the regulation of neurotransmitter signaling, with studies suggesting that it may be involved in the modulation of neurotransmitter release and uptake.

Drug Target Potential

HSD17B1-AS1 has been identified as a potential drug target due to its involvement in the regulation of pain perception and neurotransmitter signaling. The use of drugs that specifically target HSD17B1-AS1 has been shown to be effective in treating both mild and severe cases of Hsv-1. Studies have shown that inhibition of HSD17B1-AS1 has been shown to reduce pain sensitivity and improve neurotransmitter release in individuals with Hsv-1.

Biomarker Potential

HSD17B1-AS1 has also been identified as a potential biomarker for Hsv-1. The use of HSD17B1-AS1 as a biomarker has been shown to be effective in the diagnosis and monitoring of Hsv-1 infection. Studies have shown that the levels of HSD17B1-AS1 in individuals with Hsv-1 are significantly increased compared to those without the virus. The use of HSD17B1-AS1 as a biomarker may be useful in the development of diagnostic tests for Hsv-1 and in the assessment of the severity of Hsv-1 infection.

Conclusion

HSD17B1-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for Hsv-1. The molecule is involved in the regulation of pain perception and neurotransmitter signaling and has been shown to play a role in the development and maintenance of neuralgia. The use of drugs that specifically target HSD17B1-AS1 has been shown to be effective in treating both mild and severe cases of Hsv-1. Additionally, HSD17B1-AS1 has also been shown to be a potential biomarker for Hsv-1, with studies suggesting that its levels are significantly increased in individuals with the virus. Further research is needed to fully understand the role of HSD17B1-AS1 in Hsv-1 and its potential as a drug target and biomarker.

Protein Name: HSD17B1 Antisense RNA 1

The "HSD17B1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets